Literature DB >> 12692710

Urinary glycosaminoglycans in the course of familial Mediterranean fever.

Esra Baskin1, Umit Saatçi, Gönenç Ciliv, Aysin Bakkaloglu, Nesrin Besbas, Rezan Topaloglu, Seza Ozen.   

Abstract

UNLABELLED: Familial Mediterranean fever (FMF) is characterised by recurrent fever and serositis. The most important complication of the disease is amyloidosis. Cheap and non-invasive methods would be important in predicting or establishing the early diagnosis of amyloidosis. For this purpose, we studied the role of urinary glycosaminoglycans (GAG). The study group included 123 FMF patients without an attack and 11 patients with FMF associated amyloidosis. Ten healthy children and ten patients with primary nephrotic syndrome served as controls. In patients with amyloidosis, urinary GAG were lower than in patients with FMF, patients with nephrotic syndrome and controls (median and range: 8.54 mg hexuronic acid/g creatinine (1.87-25.5), 5.8 (1.7-17.26), 23.12 (8.74-28.06) and 19.25 (14.2-26.9) respectively, P<0.01). There was a significant negative correlation between the duration of the disease and urinary GAG ( r= -043, P=0.002). In 49 FMF patients with a low GAG, urinary GAG increased significantly after an increase in the colchicine dose (median and range: 6.64 mg hexuronic acid/g creatinine (1.77-19.39) and 9.45 mg hexuronic acid/g creatinine (2.36-28.9), P<0.01).
CONCLUSION: These results suggest that urinary glycosaminoglycan levels may be a predictor of amyloidosis in patients with familial Mediterranean fever. We also suggest that effective colchicine doses may be monitored by following urinary glycosaminoglycan excretion.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12692710     DOI: 10.1007/s00431-003-1173-3

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  30 in total

1.  Tumor necrosis factor in familial Mediterranean fever.

Authors:  E Ozyilkan; H Simsek; H Telatar
Journal:  Am J Med       Date:  1992-05       Impact factor: 4.965

2.  Interleukin-8 alters glomerular heparan sulfate glycosaminoglycan chain size and charge in rats.

Authors:  E H Garin; L West; W Zheng
Journal:  Pediatr Nephrol       Date:  2000-04       Impact factor: 3.714

3.  Decreased excretion of urine glycosaminoglycans as marker in renal amyloidosis.

Authors:  J Tencer; O Torffvit; A Grubb; S Björnsson; H Thysell; B Rippe
Journal:  Nephrol Dial Transplant       Date:  1997-06       Impact factor: 5.992

Review 4.  Familial Mediterranean fever-associated amyloidosis.

Authors:  J P Méry; S Kenouch
Journal:  Ren Fail       Date:  1993       Impact factor: 2.606

5.  Colchicine inhibition of serum amyloid protein SAA and SAP synthesis in primary mouse liver cell cultures.

Authors:  E Tatsuta; J D Sipe; T Shirahama; M Skinner; A S Cohen
Journal:  Arthritis Rheum       Date:  1984-03

6.  Serum soluble intercellular adhesion molecule 1 and interleukin 8 levels in familial Mediterranean fever.

Authors:  H Direskeneli; H Ozdogan; C Korkmaz; T Akoglu; H Yazici
Journal:  J Rheumatol       Date:  1999-09       Impact factor: 4.666

7.  Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF Consortium.

Authors: 
Journal:  Cell       Date:  1997-08-22       Impact factor: 41.582

8.  Effects of colchicine on inflammatory cytokines and selectins in familial Mediterranean fever.

Authors:  S Kiraz; I Ertenli; M Arici; M Calgüneri; I Haznedaroglu; I Celik; S Pay; S Kirazli
Journal:  Clin Exp Rheumatol       Date:  1998 Nov-Dec       Impact factor: 4.473

9.  Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever.

Authors:  D Zemer; M Pras; E Sohar; M Modan; S Cabili; J Gafni
Journal:  N Engl J Med       Date:  1986-04-17       Impact factor: 91.245

10.  Interaction between circulating amyloid fibril protein precursors and extracellular tissue matrix components in the pathogenesis of systemic amyloidosis.

Authors:  G Husby; T Stenstad; J H Magnus; K Sletten; B Y Nordvåg; G Marhaug
Journal:  Clin Immunol Immunopathol       Date:  1994-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.